Zoetis Announces Pricing of $1.25 Billion of Senior Notes
September 05 2017 - 5:15PM
Business Wire
Zoetis Inc. (NYSE:ZTS) today announced that it has agreed to
sell $1.25 billion of senior notes, consisting of $750 million
aggregate principal amount of 3.000% senior notes due 2027 and $500
million aggregate principal amount of 3.950% senior notes due 2047,
in an underwritten public offering.
Zoetis intends to use the net proceeds to repay, prior to
maturity, the principal (including a make-whole amount) of its
1.875% senior notes due 2018 in the aggregate principal amount of
$750 million; and for general corporate purposes. The offering is
expected to close on September 12, 2017, subject to customary
closing conditions.
Barclays Capital Inc., Citigroup Global Markets Inc., J.P.
Morgan Securities LLC, Merrill Lynch, Pierce, Fenner & Smith
Incorporated and MUFG Securities Americas Inc. are acting as joint
book-running managers of the underwriters. The final prospectus
supplement and accompanying prospectus, when available, may be
accessed through the SEC’s website at www.sec.gov. Alternatively,
the issuer, the underwriters or any dealer participating in the
offering will arrange to send you the prospectus and prospectus
supplement if you request it by calling Barclays at 1-888-603-5847,
BofA Merrill Lynch at 1-800-294-1322, Citigroup at 1-800-831-9146,
J.P. Morgan at 212-834-4533 and MUFG at 1-877-649-6848.
These securities are offered pursuant to a registration
statement that has become effective under the Securities Act of
1933, as amended. These securities are only offered by means of the
prospectus supplement and prospectus relating to the offering. This
press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any offer or
sale of these securities in any state or other jurisdiction, where
the offer, solicitation or sale of these securities would be
unlawful prior to the registration or qualification under the
securities laws of any such state or other jurisdiction.
About Zoetis
Zoetis is the leading animal health company, dedicated to
supporting its customers and their businesses. Building on more
than 60 years of experience in animal health, Zoetis discovers,
develops, manufactures and markets veterinary vaccines and
medicines, complemented by diagnostic products, genetic tests,
biodevices and a range of services. Zoetis serves veterinarians,
livestock producers and people who raise and care for farm and
companion animals with sales of its products in more than 100
countries.
DISCLOSURE NOTICES
Forward-Looking
Statements: This press release contains forward-looking
statements, which reflect the current views of Zoetis with respect
to business plans or prospects, future operating or financial
performance, future guidance, future operating models, expectations
regarding products, future use of cash and dividend payments, tax
rate and tax regimes, changes in the tax regimes and
laws in other jurisdictions, and other future events.
These statements are not guarantees of future performance or
actions. Forward-looking statements are subject to risks and
uncertainties. If one or more of these risks or uncertainties
materialize, or if management's underlying assumptions prove to be
incorrect, actual results may differ materially from those
contemplated by a forward-looking statement. Forward-looking
statements speak only as of the date on which they are made. Zoetis
expressly disclaims any obligation to update or revise any
forward-looking statement, whether as a result of new information,
future events or otherwise. A further list and description of
risks, uncertainties and other matters can be found in the
prospectus supplement and accompanying prospectus under the caption
“Risk Factors” and in our Annual Report on Form 10-K for the fiscal
year ended December 31, 2016, including in the sections thereof
captioned “Forward-Looking Statements and Factors That May Affect
Future Results” and “Item 1A. Risk Factors,” in our Quarterly
Reports on Form 10-Q and in our Current Reports on Form 8-K. These
filings and subsequent filings are available online
at www.sec.gov, Zoetis’ website, or on request from
Zoetis.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170905006538/en/
Zoetis Inc.Media:Bill Price, 1-973-443-2742
(o)william.price@zoetis.comorElinore White, 1-973-443-2835
(o)elinore.y.white@zoetis.comorInvestors:Steve Frank,
1-973-822-7141 (o)steve.frank@zoetis.com
Zoetis (NYSE:ZTS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Zoetis (NYSE:ZTS)
Historical Stock Chart
From Apr 2023 to Apr 2024